Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms
2006
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Antitumor activity of HER-2 inhibitors
2004
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Letrozole in the extended adjuvant setting: MA.17
2007
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Pancreatic cancer
2004 Standout
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer
2005
Comparing antibody and small-molecule therapies for cancer
2006
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
High-resolution cryo-electron microscopy structure of the Trypanosoma brucei ribosome
2013 StandoutNatureNobel
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Pancreatic cancer
2016 Standout
Hepatitis-C-virus-like internal ribosome entry sites displace eIF3 to gain access to the 40S subunit
2013 StandoutNatureNobel
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Pancreatic Adenocarcinoma
2014 Standout
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Gefitinib — a novel targeted approach to treating cancer
2004
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
The Eukaryotic Translation Initiation Factors eIF1 and eIF1A Induce an Open Conformation of the 40S Ribosome
2007 StandoutNobel
Pancreatic Cancer
2010 Standout
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective
2005
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Preservation of Fertility in Patients with Cancer
2009 Standout
Structure of the Mammalian Ribosomal 43S Preinitiation Complex Bound to the Scanning Factor DHX29
2013 StandoutNobel
Pancreatic cancer
2011 Standout
Estimation of variance in single-particle reconstruction using the bootstrap technique
2006 StandoutNobel
Structure and Dynamics of a Processive Brownian Motor: The Translating Ribosome
2010 StandoutNobel
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
2005
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
2005
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Decision aids for people facing health treatment or screening decisions
2017 Standout
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
2005
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Multiscale natural moves refine macromolecules using single-particle electron microscopy projection images
2012 StandoutNobel
Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy
2011
Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
2005
Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy
2005
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
2005
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
2005
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
2005
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
2007
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
2008
Works of Dongping Tu being referenced
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
2004
A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer
2005
NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months
2006
The Jackknife and Bootstrap.
1996
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.
2011